Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.42 -12.3%	$1.55	$1.03 ▼ $8.64	$44.30M	-0.27	522,015 shs	4.27 million shs
IMUC EOM Pharmaceutical	$0.07 -34.0%	$0.10	$0.01 ▼ $0.21	$8.49M	0.03	411 shs	1,917 shs
MAIA MAIA Biotechnology	$1.77 +1.7%	$1.86	$1.40 ▼ $4.24	$53.64M	0.03	220,661 shs	169,349 shs
OSTX OS Therapies	$1.84 +1.7%	$1.76	$1.12 ▼ $7.00	$51.70M	N/A	460,076 shs	254,659 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	0.00%	-5.33%	-10.13%	-21.55%	-80.73%
IMUC EOM Pharmaceutical	0.00%	-35.67%	-21.06%	-56.57%	-61.15%
MAIA MAIA Biotechnology	0.00%	-5.35%	-2.21%	+9.26%	-43.81%
OSTX OS Therapies	0.00%	+3.37%	+16.46%	+13.58%	+183,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNM Actinium Pharmaceuticals	2.2721 of 5 stars	3.4	5.0	0.0	0.0	0.9	0.0	0.6
IMUC EOM Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MAIA MAIA Biotechnology	0.6515 of 5 stars	0.0	3.0	0.0	0.0	1.0	3.3	0.0
OSTX OS Therapies	2.365 of 5 stars	3.7	0.0	0.0	0.0	1.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	2.75	Moderate Buy	$4.00	181.69% Upside
IMUC EOM Pharmaceutical	0.00	N/A	N/A	N/A
MAIA MAIA Biotechnology	0.00	N/A	N/A	N/A
OSTX OS Therapies	3.40	Buy	$18.00	878.26% Upside

Current Analyst Ratings Breakdown

Latest IMUC, MAIA, OSTX, and ATNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/12/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/28/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/2/2025	OSTX OS Therapies	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
4/1/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/31/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$81K	546.89	N/A	N/A	$1.31 per share	1.08
IMUC EOM Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A
MAIA MAIA Biotechnology	N/A	N/A	N/A	N/A	$0.14 per share	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.39	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
IMUC EOM Pharmaceutical	-$1.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MAIA MAIA Biotechnology	-$23.25M	-$1.38	N/A	N/A	N/A	N/A	-474.86%	-146.56%	8/8/2025 (Estimated)
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMUC EOM Pharmaceutical	N/A	N/A	N/A	N/A	N/A
MAIA MAIA Biotechnology	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
IMUC EOM Pharmaceutical	N/A	N/A	N/A
MAIA MAIA Biotechnology	N/A	2.35	2.35
OSTX OS Therapies	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
IMUC EOM Pharmaceutical	N/A
MAIA MAIA Biotechnology	5.65%
OSTX OS Therapies	N/A

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	6.00%
IMUC EOM Pharmaceutical	3.28%
MAIA MAIA Biotechnology	32.32%
OSTX OS Therapies	13.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
IMUC EOM Pharmaceutical	3	126.50 million	122.35 million	Not Optionable
MAIA MAIA Biotechnology	9	30.31 million	20.51 million	Not Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A

IMUC, MAIA, OSTX, and ATNM Headlines

Recent News About These Companies

OS Therapies Stock Surges 12.4% After Positive FDA Feedback on OST-HER2

June 24, 2025 | msn.com

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 24, 2025 | businesswire.com

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

June 23, 2025 | businesswire.com

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 10, 2025 | prnewswire.com

OSTX OS Therapies Incorporated

June 1, 2025 | seekingalpha.com

Buy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer Immunotherapy

May 21, 2025 | tipranks.com

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | businesswire.com

OS Therapies Launches Subsidiary To Commercialize Canine Osteosarcoma Treatment

May 16, 2025 | finanzen.atF

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

May 15, 2025 | finance.yahoo.com

OS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 82,000 Shares

May 10, 2025 | insidertrades.com

OS Therapies Inc sees $163,918 in stock sales by major shareholder

May 9, 2025 | investing.com

OS Therapies secures patent for cancer immunotherapy tech

May 8, 2025 | investing.com

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

May 2, 2025 | businesswire.com

OS Therapies granted FDA meeting for OST-HER2

April 22, 2025 | markets.businessinsider.com

OS Therapies FDA Meeting Request Granted

April 22, 2025 | businesswire.com

OS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $67,516.20 in Stock

April 12, 2025 | insidertrades.com

OS Therapies Announces Positive Data From The Study Of OST-HER2 In Osteosarcoma In Dogs

April 12, 2025 | nasdaq.com

OS Therapies Inc: Shalom Auerbach sells $81,566 in common stock

April 11, 2025 | investing.com

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

April 10, 2025 | businesswire.com

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

April 10, 2025 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUC, MAIA, OSTX, and ATNM Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.42 -0.20 (-12.35%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.44 +0.02 (+1.06%)

As of 06/27/2025 07:59 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

EOM Pharmaceutical OTCMKTS:IMUC

$0.07 -0.03 (-34.02%)

As of 06/27/2025 03:23 PM Eastern

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

MAIA Biotechnology NYSEAMERICAN:MAIA

$1.77 +0.03 (+1.72%)

Closing price 06/27/2025 04:10 PM Eastern

Extended Trading

$1.78 +0.00 (+0.28%)

As of 06/27/2025 07:56 PM Eastern

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

OS Therapies NYSE:OSTX

$1.84 +0.03 (+1.66%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.89 +0.05 (+2.72%)

As of 06/27/2025 07:57 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time